The purpose of this study is to compare the survival and toxicity of TPC (TAXOL, DDP AND CAPECITABINE ) VS PF (cisplatin and 5-Fluorouracil) as induction chemotherapy combined with concurrent chemoradiotherapy (CCRT) for stage IVa-b nasopharyngeal carcinoma patients in endemic area.

This is a prospective, parallel, randomized, open labeled, multicenter phase III clinical trial to compare the survival and toxicity of TPC VS PF as induction chemotherapy combined with CCRT for stage IVa-b nasopharyngeal carcinoma patients in endemic area.The primary endpoint is failure free survival (FFS）.The secondary endpoints are overall survival(OS）,progression-free survival（PFS）, local-regionally relapse free survival(LRFS), distant metastasis free survival（DMFS)and toxicities.

Inclusion Criteria:

• WHO II or III pathological type
• stage Ⅳa or Ⅳb (UICC 7th edition)
• no anticancer treatment before
• no malignant history
• both gender, 18-60 years old
• enough liver function: TBIL≤ULN；AST/ALT≤2.5×ULN；ALP≤5×ULN
• enough kidney function: Clcr≥80 mL/min
• enough hemo: ANC≥2×109/L, PLT≥100×109/L and HB≥9g/dL
• no sever heart, lung disfunction
• PS≤2

Exclusion Criteria:

• previous anticancer treatment
• distant metastasis
• pregnant or breasting female
• can not access to followup
• enrolled in other therapeutic clinical trial
• sever infection and internal disease
• sever disfunction of heart, lung, kidney, liver, etc
• TBIL>ULN；AST/ALT>2.5×ULN；ALP>5×ULN
• with factors that will affect the administration, distribution,metabolism or evacuation.
• using immunosuppressive agents after organ transplantation
• other malignant history

The diagnosis, treatment regimen, toxicity and followup data will be shared once every year through email, phone or meeting.